A House subcommittee approved a package of bills to overhaul drug safety oversight laws, but removed a provision that would have let the FDA impose a three-year ban on direct-to-consumer ads for newly launched drugs. Instead, the bill would allow the FDA to fine companies $250,000 for showing false or misleading ads to consumers.

Related Summaries